Genomewide Expression Profiling Identifies a Novel miRNA-based Signature for the Detection of Peritoneal Metastasis in Patients With Gastric Cancer.
Adolescent
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ biosynthesis
Female
Gene Expression Regulation, Neoplastic
Humans
Male
MicroRNAs
/ biosynthesis
Middle Aged
Oligonucleotide Array Sequence Analysis
Peritoneal Neoplasms
/ diagnosis
RNA, Neoplasm
/ biosynthesis
ROC Curve
Stomach Neoplasms
/ diagnosis
Young Adult
Journal
Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
pubmed:
31
10
2019
medline:
23
11
2021
entrez:
31
10
2019
Statut:
ppublish
Résumé
This study aimed to conduct a genomewide transcriptomic profiling to develop a microRNA (miRNA)-based signature for the identification of peritoneal metastasis (PM) in patients with gastric cancer (GC). Even though PM in patients with GC has long been recognized to associate with poor prognosis, currently there is lack of availability of molecular biomarkers for its robust diagnosis. We performed a systematic biomarker discovery by analyzing miRNA expression profiles in primary tumors from GC patients with and without PM, and subsequently validated the expression of candidate miRNA biomarkers in 3 independent clinical cohorts of 354 patients with advanced GC. Five miRNAs (miR-30a-5p, -134-5p, -337-3p, -659-3p, and -3917) were identified during the initial discovery phase; three of which (miR-30a-5p, -659-3p, and -3917) were significantly overexpressed in the primary tumors from PM-positive patients in the testing cohort (P = 0.002, 0.04, and 0.007, respectively), and distinguished patients with versus without peritoneal metastasis with the value of area under the curve (AUC) of 0.82. Furthermore, high expression of these miRNAs also associated with poor prognosis (hazard ratio = 2.18, P = 0.04). The efficacy of the combination miRNA signature was subsequently validated in an independent validation cohort (AUC = 0.74). Finally, our miRNA signature when combined together with the macroscopic Borrmann's type score offered a much superior diagnostic in all 3 cohorts (AUC = 0.87, 0.76, and 0.79, respectively). We have established an miRNA-based signature that have a potential to identify peritoneal metastasis in GC patients.
Sections du résumé
OBJECTIVE
This study aimed to conduct a genomewide transcriptomic profiling to develop a microRNA (miRNA)-based signature for the identification of peritoneal metastasis (PM) in patients with gastric cancer (GC).
SUMMARY BACKGROUND DATA
Even though PM in patients with GC has long been recognized to associate with poor prognosis, currently there is lack of availability of molecular biomarkers for its robust diagnosis.
METHODS
We performed a systematic biomarker discovery by analyzing miRNA expression profiles in primary tumors from GC patients with and without PM, and subsequently validated the expression of candidate miRNA biomarkers in 3 independent clinical cohorts of 354 patients with advanced GC.
RESULTS
Five miRNAs (miR-30a-5p, -134-5p, -337-3p, -659-3p, and -3917) were identified during the initial discovery phase; three of which (miR-30a-5p, -659-3p, and -3917) were significantly overexpressed in the primary tumors from PM-positive patients in the testing cohort (P = 0.002, 0.04, and 0.007, respectively), and distinguished patients with versus without peritoneal metastasis with the value of area under the curve (AUC) of 0.82. Furthermore, high expression of these miRNAs also associated with poor prognosis (hazard ratio = 2.18, P = 0.04). The efficacy of the combination miRNA signature was subsequently validated in an independent validation cohort (AUC = 0.74). Finally, our miRNA signature when combined together with the macroscopic Borrmann's type score offered a much superior diagnostic in all 3 cohorts (AUC = 0.87, 0.76, and 0.79, respectively).
CONCLUSIONS
We have established an miRNA-based signature that have a potential to identify peritoneal metastasis in GC patients.
Identifiants
pubmed: 31663973
pii: 00000658-202111000-00036
doi: 10.1097/SLA.0000000000003647
pmc: PMC7577555
mid: NIHMS1636561
doi:
Substances chimiques
Biomarkers, Tumor
0
MicroRNAs
0
RNA, Neoplasm
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e425-e434Subventions
Organisme : NCI NIH HHS
ID : R01 CA202797
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA184792
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA187956
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181572
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA214254
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA072851
Pays : United States
Informations de copyright
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest to disclose.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65:5–29.
Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87:236–242.
Ishizone S, Maruta F, Saito H, et al. Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer. Chemotherapy 2006; 52:301–307.
Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9:215–221.
Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer 2014; 134:622–628.
Kakroo SM, Rashid A, Wani AA, et al. Staging laparoscopy in carcinoma of stomach: a comparison with CECT staging. Int J Surg Oncol 2013; 2013:674965.
Burbidge S, Mahady K, Naik K. The role of CT and staging laparoscopy in the staging of gastric cancer. Clin Radiol 2013; 68:251–255.
Burke EC, Karpeh MS, Conlon KC, et al. Laparoscopy in the management of gastric adenocarcinoma. Ann Surg 1997; 225:262–267.
Nakagawa S, Nashimoto A, Yabusaki H. Role of staging laparoscopy with peritoneal lavage cytology in the treatment of locally advanced gastric cancer. Gastric Cancer 2007; 10:29–34.
Karanicolas PJ, Elkin EB, Jacks LM, et al. Staging laparoscopy in the management of gastric cancer: a population-based analysis. J Am Coll Surg 2011; 213:644–651. 651.e1.
Ajani JA, Bentrem DJ, Besh S, et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2013; 11:531–546.
Ramos RF, Scalon FM, Scalon MM, et al. Staging laparoscopy in gastric cancer to detect peritoneal metastases: a systematic review and meta-analysis. Eur J Surg Oncol 2016; 42:1315–1321.
Tsuchida K, Yoshikawa T, Tsuburaya A, et al. Indications for staging laparoscopy in clinical T4M0 gastric cancer. World J Surg 2011; 35:2703–2709.
Miki Y, Tokunaga M, Tanizawa Y, et al. Staging laparoscopy for patients with cM0, type 4, and large type 3 gastric cancer. World J Surg 2015; 39:2742–2747.
Li Z, Li Z, Jia S, et al. Depth of tumor invasion and tumor-occupied portions of stomach are predictive factors of intra-abdominal metastasis. Chin J Cancer Res 2017; 29:109–117.
Hosogi H, Shinohara H, Tsunoda S, et al. Staging laparoscopy for advanced gastric cancer: significance of preoperative clinicopathological factors. Langenbecks Arch Surg 2017; 402:33–39.
Nakata B, Hirakawa YSCK, Kato Y, et al. Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer 1998; 83:2488–2492.
Yamao T, Kai S, Kazami A, et al. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. Jpn J Clin Oncol 1999; 29:550–555.
Byrne DJ, Browning MC, Cuschieri A. CA72-4: a new tumour marker for gastric cancer. Br J Surg 1990; 77:1010–1013.
Emoto S, Ishigami H, Yamashita H, et al. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer 2012; 15:154–161.
Ishigami H, Kitayama J, Otani K, et al. Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology 2009; 76:311–314.
Ishigami H, Kitayama J, Kaisaki S, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 2010; 21:67–70.
Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: progress toward a new standard of care. Cancer Treat Rev 2016; 48:42–49.
Yonemura Y, Elnemr A, Endou Y, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol 2010; 2:85–97.
Yonemura Y, Canbay E, Li Y, et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol 2016; 42:1123–1131.
Ji ZH, Peng KW, Yu Y, et al. Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases. Int J Hyperthermia 2017; 33:562–570.
Yonemura Y, Endou Y, Shinbo M, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery. J Surg Oncol 2009; 100:311–316.
Fujiwara Y, Takiguchi S, Nakajima K, et al. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol 2012; 105:38–42.
Yamaguchi H, Kitayama J, Ishigami H, et al. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer 2013; 119:3354–3358.
Ishigami H, Yamaguchi H, Yamashita H, et al. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer 2017; 20:128–134.
Ishigami H, Fujiwara Y, Fukushima R, et al. Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial. J Clin Oncol 2018; 36:1922–1929.
Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487:330–337.
Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, et al. Integrated genomic characterization of oesophageal carcinoma. Nature 2017; 541:169–175.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513:202–209.
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75:843–854.
Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993; 75:855–862.
Tsai MM, Wang CS, Tsai CY, et al. Potential diagnostic, prognostic and therapeutic targets of microRNAs in human gastric cancer. Int J Mol Sci 2016; 17: pii: E945.
pii: e945
Zhang Y, Guan DH, Bi RX, et al. Prognostic value of microRNAs in gastric cancer: a meta-analysis. Oncotarget 2017; 8:55489–55510.
Zheng J, Ge P, Liu X, et al. MiR-136 inhibits gastric cancer-specific peritoneal metastasis by targeting HOXC10. Tumour Biol 2017; 39: 1010428317706207.
Zhang Y, Wu YY, Jiang JN, et al. MiRNA-3978 regulates peritoneal gastric cancer metastasis by targeting legumain. Oncotarget 2016; 7:83223–83230.
Ji FJ, Wu YY, An Z, et al. Expression of both poly r(C) binding protein 1 (PCBP1) and miRNA-3978 is suppressed in peritoneal gastric cancer metastasis. Sci Rep 2017; 7:15488.
Imaoka H, Toiyama Y, Okigami M, et al. Circulating microRNA-203 predicts metastases, early recurrence, and poor prognosis in human gastric cancer. Gastric Cancer 2016; 19:744–753.
Tsukasa K, Ding Q, Miyazaki Y, et al. miR-30 family promotes migratory and invasive abilities in CD133(+) pancreatic cancer stem-like cells. Hum Cell 2016; 29:130–137.
Che S, Sun T, Wang J, et al. miR-30 overexpression promotes glioma stem cells by regulating Jak/STAT3 signaling pathway. Tumour Biol 2015; 36:6805–6811.
Wang J, Jiao Y, Cui L, et al. miR-30 functions as an oncomiR in gastric cancer cells through regulation of P53-mediated mitochondrial apoptotic pathway. Biosci Biotechnol Biochem 2017; 81:119–126.
An JY, Kang TH, Choi MG, et al. Borrmann type IV: an independent prognostic factor for survival in gastric cancer. World J Gastrointest Oncol 2008; 12:1364–1369.
Li C, Oh SJ, Kim S, et al. Macroscopic Borrmann type as a simple prognostic indicator in patients with advanced gastric cancer. Oncology 2009; 77:197–204.
Huang B, Sun Z, Wang Z, et al. Factors associated with peritoneal metastasis in non-serosa-invasive gastric cancer: a retrospective study of a prospectively-collected database. BMC Cancer 2013; 13:57.
Hu YF, Deng ZW, Liu H, et al. Staging laparoscopy improves treatment decision-making for advanced gastric cancer. World J Gastroenterol 2016; 22:1859–1868.
Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017; 20:1–19.
Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93:2325–2327.
Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277:665–667.
Guchelaar HJ, ten Napel CH, de Vries EG, et al. Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. Clin Oncol (R Coll Radiol) 1994; 6:40–48.
Kodera Y, Takahashi N, Yoshikawa T, et al. Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial. Gastric Cancer 2017; 20:190–199.
Kobayashi D, Kodera Y. Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Gastric Cancer 2017; 20:111–121.
Yonemura Y, Ishibashi H, Hirano M, et al. Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal/systemic chemotherapy on peritoneal metastases from gastric cancer. Ann Surg Oncol 2017; 24:478–485.